Authorized Generics Practice

Abstract

Wagh MP, Patel JS, Baheti DR

Due to lower price and same quality, a number of prescriptions have been increased for generic equivalents of branded products. After the expiration of patent life, profits for an innovator company decline due to market entry of the generic version of same active pharmaceutical ingredient. To regain this loss, some branded companies have started strategies to launch their NDA - approved product under different labels through their subsidiary company or partnering with a generic firm. An authorized generic entry could affect the timing of the generic entry, brand - name and generic prices, and generic penetration. This strategy will provide benefits to customers, generic firms, and innovator firms as well.